Bladder cancer ranks among the most common cancers globally. At diagnosis, 75% of
patients have non-muscle-invasive bladder cancer (NMIBC). Patients with low-risk NMIBC …

PDD or WL Resection of Tumors in NMIBC In this open-label trial, patients with intermediate-
or high-risk non–muscle-invasive bladder cancer at diagnosis were randomly assigned to …

Purpose Despite increasing development in decision-making strategies for patients with
prostate cancer, little is known about patients' individual experience and perception …

Purpose To understand supportive care needs among people with non-muscle invasive
bladder cancer (NMIBC). Methods An integrative systematic review was reported using the …

Objective The low detection rate of early-stage and small tumors remains a clinical
challenge. A solution to this unmet need is urgently warranted for the accurate diagnosis …

Transurethral resection of bladder tumor (TURBT) followed by intravesical therapy remains
the most effective strategy for the management of non-muscle-invasive bladder cancer …

Very little is known about the impact of living with non-muscle invasive bladder cancer
(NMIBC). NMIBC patients' experiences of their illness–in terms of their perceptions, coping …

Background: We describe the oncologic and functional outcomes and the surgical technique
of the photodynamic diagnosis (PDD)-assisted en bloc transurethral resection of bladder …

Background Transurethral resection of bladder tumor (TURBT) is an essential procedure
both for the treatment and staging of bladder cancer, particularly non-muscle invasive …

BACKGROUND Around 7500 people are diagnosed with non-muscle-invasive bladder
cancer in the UK annually. Recurrence following transurethral resection of bladder tumour is …